Katharina Fink

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna, Peter Alping, Joachim Burman et al. · JAMA Neurology · 2019 · 492 citations · Full text

Rituximab in multiple sclerosis

Jonatan Salzer, Rasmus Svenningsson, Peter Alping et al. · Neurology · 2016 · 340 citations · Full text

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Peter Alping, Thomas Frisell, Lenka Novakova et al. · Annals of Neurology · 2016 · 224 citations

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

Michael B. Atkins, Joseph A. Sparano, Richard I. Fisher et al. · Journal of Clinical Oncology · 1993 · 218 citations